Korro Bio Announces Board and Executive Changes

Ticker: KRRO · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1703647

Korro Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyKorro Bio, Inc. (KRRO)
Form Type8-K
Filed DateOct 8, 2025
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: management-change, governance, filing

TL;DR

Korro Bio reshuffled its board and exec comp. Big changes coming?

AI Summary

Korro Bio, Inc. announced on October 7, 2025, changes in its board and executive compensation. The company, formerly known as Frequency Therapeutics, Inc., filed an 8-K report detailing the departure of directors, election of new directors, appointment of officers, and updates to compensatory arrangements for certain officers. These changes are effective as of October 7, 2025.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Players & Entities

  • Korro Bio, Inc. (company) — Registrant
  • Frequency Therapeutics, Inc. (company) — Former company name
  • October 7, 2025 (date) — Effective date of reportable events
  • October 8, 2025 (date) — Filing date

FAQ

What specific changes were made to Korro Bio's board of directors?

The filing indicates the departure of directors and the election of new directors, though specific names are not detailed in this excerpt.

Were there any changes to Korro Bio's executive officers?

Yes, the filing states the appointment of certain officers.

What is the effective date of the reported changes?

The earliest event reported is effective as of October 7, 2025.

What was Korro Bio's former company name?

Korro Bio, Inc. was formerly known as Frequency Therapeutics, Inc.

What is the primary business of Korro Bio, Inc.?

Korro Bio, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).

Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-10-08 07:30:26

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share KRRO The Nasdaq Capital M

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Separation Agreement and Release by and between Korro Bio, Inc. and Vineet Agarwal, dated October 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KORRO BIO, INC. Date: October 8, 2025 By: /s/ Ram Aiyar Name: Ram Aiyar Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.